$LYRA
Lyra Therapeutics, Inc.

2022 Q3 Form 10-Q Financial Statement

#000156459022028609 Filed on August 09, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $359.0K $407.0K $5.367M
YoY Change 2464.29%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.137M $4.132M $3.888M
YoY Change 27.85% 16.07% 27.06%
% of Gross Profit
Research & Development $10.05M $10.79M $8.505M
YoY Change 41.98% 43.81% 78.3%
% of Gross Profit
Depreciation & Amortization $300.0K $300.0K $300.0K
YoY Change -25.0% 0.0% 328.57%
% of Gross Profit
Operating Expenses $15.19M $14.93M $8.505M
YoY Change 36.86% 34.88% 8.61%
Operating Profit -$14.83M -$14.52M -$7.026M
YoY Change 33.8% 31.21% -10.28%
Interest Expense $60.00K $34.00K $14.00K
YoY Change 130.77% 30.77% -53.33%
% of Operating Profit
Other Income/Expense, Net $60.00K $34.00K $14.00K
YoY Change 130.77% 30.77% -51.72%
Pretax Income -$14.77M -$14.48M -$7.012M
YoY Change 33.57% 31.21% -10.1%
Income Tax
% Of Pretax Income
Net Earnings -$14.77M -$14.48M -$7.012M
YoY Change 33.57% 31.21% -10.13%
Net Earnings / Revenue -4113.09% -3558.72% -130.65%
Basic Earnings Per Share -$0.40 -$0.42 -$0.92
Diluted Earnings Per Share -$0.40 -$426.7K -$539.0K
COMMON SHARES
Basic Shares Outstanding 31.83M 33.95M 13.01M
Diluted Shares Outstanding 36.83M 33.95M 13.01M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $109.6M $120.7M $33.76M
YoY Change 88.47% 74.77% -48.94%
Cash & Equivalents $109.6M $120.7M $33.80M
Short-Term Investments
Other Short-Term Assets $2.672M $1.712M $1.800M
YoY Change -3.01% 66.7% 44.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $112.2M $122.4M $40.56M
YoY Change 84.33% 74.65% -39.78%
LONG-TERM ASSETS
Property, Plant & Equipment $3.753M $4.009M $4.275M
YoY Change -20.25% 4.05% -18.42%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.783M $1.696M $1.406M
YoY Change 210.63% 196.5% 326.06%
Total Long-Term Assets $7.233M $7.654M $6.790M
YoY Change 5.19% 22.29% 21.9%
TOTAL ASSETS
Total Short-Term Assets $112.2M $122.4M $40.56M
Total Long-Term Assets $7.233M $7.654M $6.790M
Total Assets $119.5M $130.0M $47.35M
YoY Change 76.3% 70.35% -35.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.900M $1.670M $2.408M
YoY Change -0.41% -12.06% 105.81%
Accrued Expenses $7.975M $6.391M $5.334M
YoY Change 58.86% 59.58% 77.8%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.61M $9.872M $17.80M
YoY Change -23.45% 67.21% 326.91%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $12.64M $9.133M $1.387M
YoY Change 351.12% -29.36% 15.58%
Total Long-Term Liabilities $12.64M $9.133M $1.387M
YoY Change 351.12% -29.36% 15.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.61M $9.872M $17.80M
Total Long-Term Liabilities $12.64M $9.133M $1.387M
Total Liabilities $26.24M $19.01M $19.19M
YoY Change 27.54% 0.91% 257.34%
SHAREHOLDERS EQUITY
Retained Earnings -$234.4M -$214.9M -$200.4M
YoY Change 30.37% 27.39% 27.09%
Common Stock $327.7M $325.9M
YoY Change 44.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $93.22M $111.0M $28.16M
YoY Change
Total Liabilities & Shareholders Equity $119.5M $130.0M $47.35M
YoY Change 76.3% 70.35% -35.07%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$14.77M -$14.48M -$7.012M
YoY Change 33.57% 31.21% -10.13%
Depreciation, Depletion And Amortization $300.0K $300.0K $300.0K
YoY Change -25.0% 0.0% 328.57%
Cash From Operating Activities -$10.85M -$8.470M -$11.91M
YoY Change 5.16% -350.52% 56.85%
INVESTING ACTIVITIES
Capital Expenditures -$29.00K -$14.00K $93.00K
YoY Change -94.39% -97.76% -91.98%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$29.00K -$14.00K -$93.00K
YoY Change -94.39% -97.76% -91.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -236.0K 96.49M 6.000K
YoY Change 180.95% 51497.33% -97.71%
NET CHANGE
Cash From Operating Activities -10.85M -8.470M -11.91M
Cash From Investing Activities -29.00K -14.00K -93.00K
Cash From Financing Activities -236.0K 96.49M 6.000K
Net Change In Cash -11.11M 88.00M -11.99M
YoY Change 1.8% 2890.25% 41.28%
FREE CASH FLOW
Cash From Operating Activities -$10.85M -$8.470M -$11.91M
Capital Expenditures -$29.00K -$14.00K $93.00K
Free Cash Flow -$10.82M -$8.456M -$12.00M
YoY Change 10.41% -311.08% 37.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-214893000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001327273
CY2022Q2 us-gaap Alternative Investment Change In Valuation Technique
AlternativeInvestmentChangeInValuationTechnique
false
CY2021Q2 us-gaap Alternative Investment Change In Valuation Technique
AlternativeInvestmentChangeInValuationTechnique
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P2Y1M6D
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y8M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y3M18D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y9M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y8M12D
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9M18D
dei Document Type
DocumentType
10-Q
dei Document Transition Report
DocumentTransitionReport
false
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
120669000
CY2022Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
329000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1383000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2171000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1355000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1670000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1074000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
9789000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18246000
CY2022Q2 us-gaap Liabilities
Liabilities
19005000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31826357
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31826357
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13007178
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13007178
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
32000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
13000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
325891000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
227700000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-193397000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
111030000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
34316000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
130035000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
54867000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
407000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5774000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10793000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7505000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19298000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12275000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4132000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3560000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8020000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6621000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
14925000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
11065000
us-gaap Operating Expenses
OperatingExpenses
27318000
us-gaap Operating Expenses
OperatingExpenses
18896000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14518000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11065000
us-gaap Operating Income Loss
OperatingIncomeLoss
-21544000
us-gaap Operating Income Loss
OperatingIncomeLoss
-18896000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
34000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
26000
us-gaap Investment Income Interest
InvestmentIncomeInterest
48000
us-gaap Investment Income Interest
InvestmentIncomeInterest
55000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
34000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
26000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
48000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
55000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-14484000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-11039000
us-gaap Net Income Loss
NetIncomeLoss
-21496000
us-gaap Net Income Loss
NetIncomeLoss
-18841000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14484000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11039000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21496000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18841000
CY2022Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.85
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.91
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.45
CY2022Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33946428
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12991837
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23535442
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12968820
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
74492000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
262000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
599000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-7802000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
67551000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
331000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
656000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-11039000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
57499000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
34316000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
844000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7012000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
28156000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
4244000
CY2022Q2 lyra Stock Issued During Period Value Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs
StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts
96251000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1107000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-14484000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
111030000
us-gaap Profit Loss
ProfitLoss
-21496000
us-gaap Profit Loss
ProfitLoss
-18841000
us-gaap Share Based Compensation
ShareBasedCompensation
1951000
us-gaap Share Based Compensation
ShareBasedCompensation
1255000
us-gaap Depreciation
Depreciation
566000
us-gaap Depreciation
Depreciation
373000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-788000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-297000
lyra Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-495000
lyra Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-467000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
949000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1639000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
743000
lyra Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
1207000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-524000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-481000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-774000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
12000000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4209000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1785000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1785000
lyra Proceeds From Sale Of Common Stock And Pre Funded Warrant Net
ProceedsFromSaleOfCommonStockAndPreFundedWarrantNet
100495000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
4010000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
146000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
8000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
593000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
96493000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
447000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
76011000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5547000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
46076000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
74922000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
122087000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
69375000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
6000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
363000
lyra Deferred Offering Costs Incurred But Not Yet Paid
DeferredOfferingCostsIncurredButNotYetPaid
236000
lyra Deferred Offering Costs Incurred But Not Yet Paid
DeferredOfferingCostsIncurredButNotYetPaid
97000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2005-11-21
lyra Cash Provided By Financing Activities
CashProvidedByFinancingActivities
345400000
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
162100000
lyra Proceeds From Government Contracts
ProceedsFromGovernmentContracts
16800000
lyra Proceeds From License And Collaboration Agreement
ProceedsFromLicenseAndCollaborationAgreement
12000000.0
us-gaap Net Income Loss
NetIncomeLoss
-21500000
us-gaap Net Income Loss
NetIncomeLoss
-18800000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-214900000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
120700000
CY2020Q1 lyra Number Of Patients
NumberOfPatients
67
CY2022Q4 lyra Employer Side Social Security Payments Due Percentage
EmployerSideSocialSecurityPaymentsDuePercentage
0.50
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:9.06%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of expenses during the reporting period. On an ongoing basis, the Company’s management evaluates its estimates, which include but are not limited to management’s judgments of revenue recognition, operating lease right-of-use assets, operating lease liabilities, accrued expenses, valuation of share-based awards and deferred income taxes. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates. </p>
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
1400000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
300000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4060079
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1764499
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
656000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1951000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1255000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.24
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3544000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1118220
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.79
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1371000
CY2022Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
0
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
0
CY2022Q2 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
0
CY2021Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
0
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
486000
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
115000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
147000
CY2022Q2 lyra Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
5465000
CY2021Q4 lyra Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
4258000
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8454000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8382000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4445000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3879000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4009000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4503000
CY2022Q2 us-gaap Depreciation
Depreciation
300000
CY2021Q2 us-gaap Depreciation
Depreciation
300000
us-gaap Depreciation
Depreciation
600000
us-gaap Depreciation
Depreciation
400000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2718
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.76
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
24166
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.10
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4017726
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2087000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2429000
CY2022Q2 lyra Third Party Research And Development Expenses Current
ThirdPartyResearchAndDevelopmentExpensesCurrent
2714000
CY2021Q4 lyra Third Party Research And Development Expenses Current
ThirdPartyResearchAndDevelopmentExpensesCurrent
1196000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
549000
us-gaap Common Stock Voting Rights
CommonStockVotingRights
The holders of common stock are entitled to one vote for each share held.
lyra Common Stock Voting Rights Number Of Votes
CommonStockVotingRightsNumberOfVotes
1
CY2021Q2 lyra Stock And Wrrants To Be Issued During Period Value Preferred Stock And Warrants
StockAndWrrantsToBeIssuedDuringPeriodValuePreferredStockAndWarrants
250000000.0
CY2022Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10830112
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1107000
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
11628000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.032
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.009
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.025
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.007
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.806
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.847
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.807
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.853
CY2021Q2 us-gaap Variable Lease Cost
VariableLeaseCost
1243000
us-gaap Variable Lease Cost
VariableLeaseCost
2874000
us-gaap Variable Lease Cost
VariableLeaseCost
1362000
CY2022Q2 us-gaap Lease Cost
LeaseCost
2260000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
45483
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.79
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
1302
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
4.89
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
1828
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
4.78
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
42353
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.78
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1662861
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.34
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
918000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2381749
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.07
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4017726
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.24
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
3544000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.73
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.49
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.24
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.28
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
CY2022Q2 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
one additional 5-year term
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
264000
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
264000
us-gaap Operating Lease Cost
OperatingLeaseCost
528000
us-gaap Operating Lease Cost
OperatingLeaseCost
528000
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
1996000
CY2021Q2 us-gaap Lease Cost
LeaseCost
1507000
us-gaap Lease Cost
LeaseCost
3402000
us-gaap Lease Cost
LeaseCost
1890000
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.055
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
569000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
382000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
953000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
24000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
929000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
926000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3000
CY2021Q2 lyra Future Milestone Payments Receivable Upon Achievement Of Specified Development Regulatory And Commercialization
FutureMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialization
135000000.0
CY2022Q2 us-gaap Deferred Revenue
DeferredRevenue
8300000
CY2022Q2 lyra Deferred Revenue Related To Development Activites
DeferredRevenueRelatedToDevelopmentActivites
2700000
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45747000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
122381000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
329000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1696000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
762000
CY2021Q4 us-gaap Assets
Assets
54867000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
47918000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4503000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3125000
CY2021Q4 lyra Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
4258000
CY2022Q2 lyra Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
5465000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
926000
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Entity File Number
EntityFileNumber
001-39273
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1700838
dei Entity Address Address Line1
EntityAddressAddressLine1
480 Arsenal Way
dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
393-4600
dei Trading Symbol
TradingSymbol
LYRA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4009000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
860000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1089000
CY2022Q2 us-gaap Assets
Assets
130035000
dei Entity Registrant Name
EntityRegistrantName
Lyra Therapeutics, Inc.
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31826357
CY2022Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1811000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9872000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
379000
CY2022Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
9130000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1926000
CY2021Q4 us-gaap Liabilities
Liabilities
20551000
CY2021Q4 lyra Employer Side Social Security Payments Due Percentage
EmployerSideSocialSecurityPaymentsDuePercentage
0.50
lyra Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-22000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20375000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
107000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-107000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
72000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5000

Files In Submission

Name View Source Status
0001564590-22-028609-index-headers.html Edgar Link pending
0001564590-22-028609-index.html Edgar Link pending
0001564590-22-028609.txt Edgar Link pending
0001564590-22-028609-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
gvisbpbni45o000001.jpg Edgar Link pending
gvisbpbni45o000002.jpg Edgar Link pending
gvisbpbni45o000003.jpg Edgar Link pending
gvisbpbni45o000004.jpg Edgar Link pending
gvisbpbni45o000005.jpg Edgar Link pending
gvisbpbni45o000006.jpg Edgar Link pending
gvisbpbni45o000007.jpg Edgar Link pending
gvisbpbni45o000008.jpg Edgar Link pending
gvisbpbni45o000009.jpg Edgar Link pending
gvisbpbni45o000010.jpg Edgar Link pending
gvisbpbni45o000011.jpg Edgar Link pending
gvisbpbni45o000012.jpg Edgar Link pending
gvisbpbni45o000013.jpg Edgar Link pending
gvisbpbni45o000014.jpg Edgar Link pending
lyra-10q_20220630.htm Edgar Link pending
lyra-20220630.xsd Edgar Link pending
lyra-ex101_67.htm Edgar Link pending
lyra-ex102_68.htm Edgar Link pending
lyra-ex103_69.htm Edgar Link pending
lyra-ex311_6.htm Edgar Link pending
lyra-ex312_7.htm Edgar Link pending
lyra-ex321_8.htm Edgar Link pending
lyra-ex322_9.htm Edgar Link pending
lyra-ex42_66.htm Edgar Link pending
lyra-ex43_65.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
lyra-20220630_pre.xml Edgar Link unprocessable
lyra-20220630_cal.xml Edgar Link unprocessable
lyra-20220630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
lyra-10q_20220630_htm.xml Edgar Link completed
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
lyra-20220630_def.xml Edgar Link unprocessable